Global Benign Prostatic Hyperplasia Treatment Market Size, Share & Trends Analysis Report By Treatment Type (Pharmacological treatmentAlpha-blockersTamsulosinSilodosinAlfuzosinDoxazosinOther alpha-blockers5-alpha reductase inhibitors (5-ARI)DutasterideFinasterideCombination therapyAlpha-blockers + 5-arisAlpha-blockers + pde5 inhibitorsPhosphodiesterase-5 inhibitors (pde5 inhibitors)Herbal and other drugs, Surgical treatmentTransurethral resection of the prostate (TURP)Transurethral incision of t

Benign Prostatic Hyperplasia Treatment Market Size

Global Benign Prostatic Hyperplasia Treatment Market size is projected at USD 14,689.03 million in 2026 and is expected to hit USD 23,100.36 million by 2034 with a CAGR of 5.8%. The 2025 base-year valuation was USD 13,880.91 million, indicating an absolute increase of USD 9,219.45 million through 2034. Market assessment requires treatment-level, geographic and patient-demand data alongside evaluation of pharmaceutical, surgical and minimally invasive portfolios and the competitive landscape.

Key Takeaways

• North America dominates with 30.4% of 2026 revenue and advances at a 5.77% CAGR; Europe records the fastest regional CAGR at 5.99%.
• Pharmacological treatment leads with approximately 42.1% of treatment-type revenue in 2026 and a 5.98% CAGR.
• Minimally invasive procedures represent approximately 22.7% in 2026 and expand at a 5.94% CAGR, supported by outpatient technologies.
• Asia Pacific contributes approximately 26.7% of 2026 regional revenue and reaches USD 6,135.51 million by 2034 at a 5.73% CAGR.
• The Global Benign Prostatic Hyperplasia Treatment Market Growth outlook reflects an increase from USD 13.88 billion in 2025 to USD 23.10 billion by 2034.

Benign prostatic hyperplasia (BPH) treatment encompasses pharmacological therapy, surgery, minimally invasive procedures and conservative management used to relieve lower urinary tract symptoms associated with non-malignant prostate enlargement. In 2026, pharmacological treatment contributes 42.1% of treatment-type revenue, versus 25.2% for surgical treatment, 22.7% for minimally invasive procedures and 10.1% for other treatments. Regionally, North America, Europe and Asia Pacific collectively represent approximately 85.0% of 2026 revenue. The treatment landscape serves a large aging male population; contemporary clinical discussion indicates that BPH prevalence and associated LUTS rise substantially with age, sustaining high utilization of medication and procedural care.

Benign Prostatic Hyperplasia Treatment Market Trends

Shift Toward Minimally Invasive and Function-Preserving Therapies

Treatment pathways are moving from medication-only and conventional TURP approaches toward HoLEP, Rezūm, UroLift-type implants and water-based technologies. Clinical literature published in 2025 identifies HoLEP, Rezūm and Aquablation among prominent evolving interventions, with HoLEP demonstrating durable outcomes and Rezūm offering outpatient treatment while preserving sexual function.

Technology development is increasingly focused on prostate volumes measured in tens of cubic centimeters and shorter procedural pathways. The FDA-cleared Rezūm System received a substantially-equivalent decision in June 2025, while newer implant technologies broaden device-based intervention. The 2026 Zenflow Spring Implant indication covers prostate sizes of 25–80 cc, illustrating continuing innovation in minimally invasive BPH care.

Benign Prostatic Hyperplasia Treatment Market Drivers

Aging Male Population and Rising Treatment Utilization

Age-related prostate enlargement creates a structurally expanding treatment pool. Clinical evidence consistently identifies increasing BPH prevalence with age, while pharmacological therapy, endoscopic procedures and surgery provide multiple escalation pathways. The treatment continuum spans daily drug dosing, outpatient interventions and procedures for prostates commonly measured at 30–80 cc or larger, supporting utilization across millions of aging men and increasing demand for therapies balancing symptom relief, durability and preservation of sexual function.

Benign Prostatic Hyperplasia Treatment Market Restraints

Adverse Effects, Retreatment Risk and Procedure-Specific Limitations

Treatment selection remains constrained by medication side effects, perioperative risks and anatomical eligibility. Pharmacological therapy may generate troublesome adverse effects, encouraging some patients to consider procedural alternatives. Meanwhile, implant and thermal technologies can carry defined anatomical ranges; for example, recent FDA-approved implant indications specify prostate volumes such as 25–80 cc or 30–80 cc, limiting universal applicability and maintaining the need for multiple therapeutic pathways.

Benign Prostatic Hyperplasia Treatment Market Opportunities

Expansion of Outpatient and Sexual-Function-Preserving Procedures

The strongest opportunity lies in bridging long-term medication and invasive surgery. Rezūm can be delivered in outpatient settings, while emerging procedures emphasize preservation of sexual function and shorter recovery pathways. Device innovation addressing prostates from approximately 25 cc to 80 cc expands the eligible population, while new implants and thermal systems create additional competition across office-based and ambulatory urology environments.

Challenges in Global Benign Prostatic Hyperplasia Treatment Market

Clinical Evidence, Physician Training and Technology Selection

The proliferation of TURP, HoLEP, Rezūm, UroLift-type systems, Aquablation and newer implants complicates treatment selection. Evidence reviews note that additional multicenter randomized trials remain necessary for representative comparisons across therapies. Outcomes also depend on prostate anatomy, patient priorities and procedural expertise, creating training and infrastructure requirements even as technology addresses glands ranging from below 30 cc to 80 cc and substantially larger volumes.

Benign Prostatic Hyperplasia Treatment Market Segmentation

Treatment-type segmentation is led by pharmacological therapy at approximately 42.1% of 2026 treatment revenue, followed by surgery at 25.2%, minimally invasive procedures at 22.7% and other treatments at 10.1%.

By Treatment Type

Pharmacological treatment is the largest category, increasing from USD 5,838.31 million in 2025 to USD 6,187.44 million in 2026 and USD 9,846.96 million by 2034 at a 5.98% CAGR. It includes alpha-blockers such as tamsulosin, silodosin, alfuzosin and doxazosin; 5-ARIs including dutasteride and finasteride; combination therapies; PDE5 inhibitors; and herbal or other drugs.

Surgical treatment rises from USD 3,699.19 million in 2026 to USD 5,768.14 million by 2034 at 5.71%, while minimally invasive procedures expand from USD 3,330.79 million to USD 5,284.77 million at 5.94%. Other treatments reach USD 2,277.06 million by 2034 at 5.56%. Pharmacological treatment therefore remains the largest and fastest-growing supplied treatment category by CAGR.

By End Use

Hospitals, clinics, ambulatory surgical centres and specialty urology centers constitute the end-use structure. Hospitals retain importance for TURP, prostatectomy and complex laser procedures, while clinics and specialty centers support diagnosis, pharmaceutical management and follow-up. Ambulatory centers increasingly benefit from office-compatible minimally invasive interventions.

The transition toward outpatient procedures is supported by technologies such as Rezūm and implant-based systems, enabling selected patients to move away from inpatient surgery. No numerical end-use split or CAGR was supplied; therefore, no unsupported segment value is assigned.

By Patient Age Group

The market covers patients below 50 years, 50–60 years and above 60 years. Clinical burden rises sharply with aging, positioning the above-60 population as the principal treatment pool, while younger groups contribute through earlier symptomatic management and long-duration pharmacotherapy.

Treatment intensity varies with symptom severity, prostate volume and comorbidity. No age-group revenue or CAGR data were supplied, so numerical market allocation is not extrapolated beyond the mandatory dataset.

By Distribution Channel

Hospital pharmacies, retail pharmacies and online pharmacies distribute alpha-blockers, 5-ARIs, PDE5 inhibitors and combination therapies. Retail and hospital channels remain central to prescription fulfillment, while online channels extend refill accessibility for chronic medication users.

Distribution economics primarily relate to the USD 6,187.44 million pharmacological category in 2026, which reaches USD 9,846.96 million by 2034 at 5.98%. Channel-level CAGR figures were not provided and are therefore not fabricated.

Benign Prostatic Hyperplasia Treatment Market Regional Outlook

North America Benign Prostatic Hyperplasia Treatment Market 

North America leads with approximately 30.4% of 2026 revenue, rising from USD 4,228.13 million in 2025 to USD 4,472.09 million in 2026 and USD 7,005.04 million by 2034 at a 5.77% CAGR. The U.S. anchors regional procedure and pharmaceutical utilization, supported by active FDA pathways for Rezūm and new implant technologies.

Europe Benign Prostatic Hyperplasia Treatment Market 

Europe contributes approximately 27.9% in 2026, expanding from USD 4,092.98 million to USD 6,518.67 million by 2034 at 5.99%, the highest supplied regional CAGR. Germany, France, Italy, Spain and the UK form major treatment centers, with pharmaceuticals, TURP, HoLEP and minimally invasive approaches supporting regional activity.

APAC Benign Prostatic Hyperplasia Treatment Market 

Asia Pacific accounts for approximately 26.7% in 2026, increasing from USD 3,928.84 million to USD 6,135.51 million by 2034 at 5.73%. China, Japan, India, South Korea and Australia provide expanding patient pools, with aging demographics supporting pharmaceutical and procedural volumes.

Middle East and Africa Benign Prostatic Hyperplasia Treatment Market 

Middle East and Africa represents approximately 8.8% in 2026. Revenue advances from USD 1,299.34 million in 2026 to USD 2,053.83 million by 2034 at 5.89%, supported by expanding specialist urology capacity and hospital-based intervention.

Latin America Benign Prostatic Hyperplasia Treatment Market 

Latin America contributes approximately 6.1% in 2026, increasing from USD 895.78 million to USD 1,387.31 million by 2034 at 5.62%. Brazil and Mexico represent important regional treatment centers, with pharmaceutical management remaining broadly accessible alongside expanding surgical capacity.

Top players in Global Benign Prostatic Hyperplasia Treatment Market

1. Boston Scientific Corporation
2. Teleflex Incorporated
3. Olympus Corporation
4. KARL STORZ
5. PROCEPT BioRobotics
6. GlaxoSmithKline
7. Astellas Pharma
8. Viatris
9. Teva Pharmaceutical Industries
10. Sanofi
11. Bayer
12. Eli Lilly and Company
13. Proverum
14. Zenflow

Top Two Companies

• Boston Scientific Corporation: A major procedural competitor through Rezūm water-vapor therapy and broader urology capabilities. The FDA recorded a new Rezūm System 510(k) substantially-equivalent decision on June 11, 2025. Company-specific percentage share was not supplied in the mandatory dataset and is therefore not estimated.

• Teleflex Incorporated: A prominent minimally invasive BPH participant through the UroLift platform, positioned between medication and conventional tissue-removing surgery. Minimally invasive therapies increasingly address patient preferences for faster recovery and preservation of sexual function. No verified company-level percentage share was supplied, so a numerical share is not fabricated.

Recent Developments in Global Benign Prostatic Hyperplasia Treatment Market

• 2026: FDA approved the Zenflow Spring Implant and Delivery System for obstructive LUTS secondary to BPH in men with prostate sizes of 25–80 cc.
• 2025: FDA approved Proverum's ProVee System for BPH on December 9, covering specified prostate volumes of 30–80 cc.
• 2025: Boston Scientific received an FDA substantially-equivalent decision for the Rezūm System on June 11.
• 2025: Published clinical review highlighted HoLEP, Rezūm and Aquablation as evolving alternatives to conventional TURP-centered procedural pathways.
• 2025: Contemporary clinical literature emphasized UroLift, Rezūm and other minimally invasive surgical therapies as options bridging pharmacotherapy and conventional endoscopic management.